For the first time, a fluorescent-guided nerve imaging agent shows promise for use in humans, according to a paper published in Nature Communications.

Currently, the Company is exploring the use of Bucillamine for the potential treatment of nerve agent exposure and long COVID.

TORONTO, July 08, 2025 (GLOBE NEWSWIRE) — Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialized life sciences company dedicated to the research ...

Revive Therapeutics is a life sciences company focused on the research and development of therapeutics for infectious diseases and medical countermeasures. Revive prioritizes its drug development ...

AstraZeneca is in advanced talks with Summit Therapeutics over a potential $15 billion deal for the lung cancer drug ivonescimab.

Ex-Liverpool free agent on Middlesbrough radar, new kit update, sixth signing confirmed All the latest Championship news as the race heats up for former Sheffield United forward Rhian Brewster ...

For the first time, a fluorescent-guided nerve imaging agent shows promise for use in humans, according to a paper published in Nature Communications . The study sought to evaluate the safety of ...